China grants Enhertu approval for Daiichi Sankyo stock

Published on 10/25/2026 at 02:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Enhertu won conditional China approval on October 22, 2026, for HER2-positive solid tumors. Daiichi Sankyo stock reports results October 30.

October oncology and earnings dates

China granted Enhertu conditional approval on October 23, 2026, after four phase 2 trials.
Daiichi Sankyo planned more than 30 ESMO abstracts on October 22, 2026.
Daiichi Sankyo will publish second-quarter results on October 30, 2026.

Daiichi Sankyo, JP3475350009, Illustration mit AI erstellt.

Daiichi Sankyo stock (ISIN JP3475350009) has a fresh China catalyst: Enhertu received conditional approval for previously treated HER2-positive solid tumors after evidence from four phase 2 trials, Morningstar reported on October 23, 2026. The decision broadens the commercial reach of the antibody-drug conjugate while the company prepares its second-quarter results.

China adds another Enhertu indication

The approval covers adults with unresectable or metastatic solid tumors that test strongly positive for HER2 and have received prior treatment or have no satisfactory alternative options. The National Medical Products Administration decision followed responses observed across four phase 2 trials, according to Morningstar.

The regulatory step matters because Enhertu is jointly developed with AstraZeneca and targets a broad tumor-agnostic treatment setting. The commercial opportunity is balanced by the need to convert clinical progress into sustained approvals and treatment adoption.

What does the pipeline add?

Daiichi Sankyo said on October 22, 2026, that it would present more than 30 abstracts, including four late-breaking presentations, at the European Society for Medical Oncology Congress. The program covers six landmark trials involving Enhertu and Datroway across breast and lung cancer, Daiichi Sankyo said.

Three milestones frame the story

On October 16, 2026, Daiichi Sankyo scheduled its second-quarter financial results for October 30 at 1:00 p.m. JST. On October 22, the company detailed more than 30 ESMO abstracts. On October 23, China granted the Enhertu approval after four phase 2 trials, creating the latest milestone for the oncology portfolio.

Dates for the next readout

The next scheduled research event includes Daiichi Sankyo presentations on October 26, 2026, at the ESMO Congress, while the company will release second-quarter results on October 30, 2026, at 1:00 p.m. JST, according to its investor-relations calendar Daiichi Sankyo.

Stock context for investors

Daiichi Sankyo is listed on the Tokyo Stock Exchange under ticker 4568 and focuses on oncology, with its antibody-drug conjugate portfolio central to the current strategy. The company also develops cardiovascular and other specialty medicines, but the China approval and the ESMO program place oncology execution at the center of the next investor assessment.

The further course of trading is shown by the continuously updated real-time quote of Daiichi Sankyo stock.